Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Adaptive Biotechnologies and Amgen.
ASH: Medical Crossfire®: How the Experts Treat Acute Lymphoblastic Leukemia: Case Discussions From Adolescent to Adult
November 30, 2018
Lunch and registration: 12:30 PM – 1:30 PM
Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 8-9
Meeting Room: Grand Ballroom 8-9
333 W. Harbor Drive
San Diego, CA 92101
Registration is complimentary, but seating is limited.
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy that can present at different stages of life. Great progress is being made with understanding of new cytogenetic and molecular abnormalities associated with ALL and its pathophysiology, as well as development of novel targeted agents for the treatment of patients with this disease. The addition of tyrosine kinase inhibitors, monoclonal antibodies, and novel immune therapies (eg, bispecific T-cell engager [BiTE], chimeric antigen receptor [CAR] T cells) to the treatment landscape has resulted in improved clinical outcomes. These new developments have shifted clinical management from a “one-size-fits-all” approach to a more individualized treatment approach based on immunophenotypic, cytogenetic, and molecular features. Optimal treatment strategies for ALL incorporate a multitude of factors that may be particularly challenging to implement for any busy clinician.
This Medical Crossfire® will provide an ideal format for you to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda centered on the contemporary management of patients with ALL. You will have the opportunity to absorb the perspectives of leading clinical experts on a variety of different patient scenarios, and to reflect on their handling of these cases as they integrate relevant evidence into real-world practice. You will also be able to compare your patient care approaches with those of the faculty and other participating clinicians. Faculty will discuss factors that may influence risk stratification and treatment decisions, methods to best integrate the latest therapies into ALL treatment paradigms, barriers to optimized integration of these novel agents, and best practices to assist you with the management of adverse events.
This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the treatment of patients with ALL. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.
After successful completion of this educational activity, participants should be better prepared to:
- Identify prognostic factors that are essential for ALL risk stratification, and develop appropriate treatment plans for individual patients based on cytogenetic and immunophenotypic study results
- Evaluate the clinical utility of minimal residual disease assessment and how this may inform treatment decision making for adolescents and adults
- Discuss novel strategies for the management of ALL in multiple settings, including monoclonal antibodies, antibody drug conjugates, and CAR T-cell therapies
- Identify patients in multiple lines of care who may be eligible for emerging ALL treatment approaches
Acknowledgment of Commercial SupportThis activity is supported by educational grants from Adaptive Biotechnologies and Amgen.
Elias Jabbour, MD
Associate Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.